One of the FDA’s concerns about the device is the high peri-procedural stroke rate observed during the trial. While the device was effective in 56 percent of the 138 patients receiving the treatment, four of them suffered strokes within seven days. An FDA advisory panel is scheduled to tomorrow to discuss the device.
Related Articles about FDA Device Approval:
Is There a Middle Ground for Medical Device Approval?
Cook Medical’s GI Stent Approved by the FDA
GE’s New MRI Machine Gets FDA Approval
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
